



## Five novel norcembranoids from *Sinularia leptoclados* and *S. parva*

Atallah F. Ahmed,<sup>a,b</sup> Ru-Ting Shiue,<sup>a</sup> Guey-Horng Wang,<sup>a</sup> Chang-Feng Dai,<sup>c</sup> Yao-Haur Kuo<sup>d</sup> and Jyh-Horng Sheu<sup>a,\*</sup>

<sup>a</sup>Department of Marine Resources, National Sun Yat-Sen University, Kaohsiung 804, Taiwan, ROC

<sup>b</sup>Department of Pharmacognosy, Faculty of Pharmacy, Mansoura University, Mansoura 35516, Egypt

<sup>c</sup>Institute of Oceanography, National Taiwan University, Taipei 106, Taiwan, ROC

<sup>d</sup>National Research Institute of Chinese Medicine, Taipei 112, Taiwan, ROC

Received 8 April 2003; revised 15 July 2003; accepted 23 July 2003

**Abstract**—Three new norcembrane-based diterpenoids, leptocladolides A (**1**), B (**4**) and C (**5**), along with five known metabolites **6–10**, have been isolated from the dichloromethane extract of a Taiwanese soft coral *Sinularia leptoclados*. Furthermore, a chemical investigation on the dichloromethane extract of *S. parva* has resulted in the isolation of two new related isomers, 1-*epi*-leptocladolide A (**2**) and 7*E*-leptocladolide A (**3**), in addition to **1** and **7**. The structures of new metabolites **1–5** were elucidated on the basis of extensive spectroscopic analyses and their relative stereochemistries were determined by NOESY experiments. The new metabolites **1** and **3** have been shown to exhibit significant cytotoxic activity against KB and Hepa59T/VGH cancer cell lines.

© 2003 Elsevier Ltd. All rights reserved.

### 1. Introduction

Since the first discovery of the C-4 norcembrane-based diterpenoid **9** from a soft coral, *Sinularia lepoclados* Ehrenberg, by an Australian group,<sup>1</sup> several related norditerpenoids have been discovered during the investigations of other *Sinularia* species.<sup>2–10</sup> During the course of our investigation on the bioactive metabolites of Taiwanese soft corals,<sup>11–15</sup> four norditerpenoids, scabrolides A–D were isolated from *Sinularia scabra*.<sup>16</sup> Our recent investigation on the chemical constituents of *S. lepoclados* Ehrenberg has led to the isolation and identification of three new norditerpenoids; leptocladolides A (**1**), B (**4**), and C (**5**), along with five known metabolites **6–10** (Fig. 1). Also, *Sinularia parva* Tixier-Durivault which is investigated for the first time afforded leptocladolide A (**1**), and its related isomers 1-*epi*-leptocladolide A (**2**) and 7*E*-leptocladolide A (**3**), in addition to the known metabolite **7** (Fig. 1). The molecular structures, including the relative configuration of the new norditerpenoids, were elucidated by the extensive spectral analyses. The new metabolites **1–3** represent a new class of bicyclic norcembrane-based diterpenoids lacking C-5,8 ether linkages. Cytotoxicity of metabolites **1–10** against KB (human oral epidermoid

carcinoma) and Hepa59T/VGH (human liver carcinoma) cancer cell lines also is reported.


### 2. Results and discussion

Organisms of *S. leptoclados* were homogenized with EtOAc and filtered. The organic layers were combined and evaporated under vacuum to afford a dark brownish viscous residue. The residue was triturated with *n*-hexane and subsequently with dichloromethane. The dichloromethane extract was subjected to a series of chromatographic purification, including HPLC, to afford metabolites **1**, **4** and **5–10**. The dichloromethane fraction from the ethanolic extract of *S. parva* was purified by chromatography to yield compounds **1–3**, and **7** (see Section 3).

Leptocladolide A (**1**) was obtained as a colorless oil. Its HRFABMS spectrum exhibited a pseudomolecular ion peak at  $m/z$  377.1964, consistent with the molecular formula  $C_{21}H_{28}O_6$  and eight degrees of unsaturation. The IR spectrum of **1** suggested the presence of hydroxy, ester carbonyl, and keto-carbonyl functionalities by absorptions at  $\nu_{max}$  3420, 1750, 1700, 1680  $cm^{-1}$ , respectively. The FABMS exhibited peaks at  $m/z$  359  $[M+H-H_2O]^+$  and 331  $[M+H-EtOH]^+$ , revealing the presence of a hydroxy and an ethoxy group in **1**. The  $^{13}C$  NMR spectrum of **1** measured in  $CDCl_3$ , showed signals of 21 carbon atoms, which were identified by the assistance of DEPT spectrum as three

**Keywords:** *Sinularia leptoclados*; *S. parva*; leptocladolide A–C; 1-*epi*-leptocladolide; 7*E*-leptocladolide; soft coral.

\* Corresponding author. Tel.: +886-7-5252000x5030; fax: +886-7-5255020; e-mail: sheu@mail.nsysu.edu.tw



**Figure 1.** Structures of new metabolites **1–5** and known norcembranoids **6–10** of *Sinularia leptoclados* and *S. parva*.

methyls, five  $sp^3$  methylenes (including one oxymethylene), one  $sp^2$  methylene, four  $sp^3$  methines (including three oxymethines), two vinylic methines, and six  $sp^2$  quaternary carbons (Table 1). The signals appearing at  $\delta$  205.9, 199.1, and 168.2 were attributable to carbons of a normal ketone,

an  $\alpha,\beta$ -conjugated ketone, and an ester carbonyl, respectively. Furthermore, the six carbon signals appearing at  $\delta_C$  154.4 (s), 146.2 (d), 146.1 (s), 130.6 (s), 124.6 (d), and 111.2 (t) designate the presence of two trisubstituted and one 1,1-disubstituted carbon–carbon double bonds in **1**. From

**Table 1.**  $^{13}\text{C}$  NMR spectral data of compounds **1–6** and **10**

C#	<b>1</b> <sup>a</sup>	<b>2</b> <sup>a</sup>	<b>3</b> <sup>a</sup>	<b>4</b> <sup>b</sup>	<b>5</b> <sup>b</sup>	<b>6</b> <sup>b,16</sup>	<b>10</b> <sup>c</sup>
1	38.1 (d) <sup>d</sup>	41.3 (d)	39.1 (d)	39.8 (d)	44.4 (d)	40.8 (d)	41.9 (d)
2	45.1 (t)	46.5 (t)	43.2 (t)	49.9 (t)	38.6 (t)	48.3 (t)	48.2 (t)
3	205.9 (s)	207.1 (s)	205.9 (s)	208.4 (s)	108.7 (s)	207.6 (s)	208.2 (s)
4	43.0 (t)	43.5 (t)	46.4 (t)	43.9 (t)	35.2 (t)	44.8 (t)	44.5 (t)
5	82.3 (d)	81.5 (d)	81.2 (d)	78.1 (d)	77.3 (d)	75.0 (d)	77.5 (d)
6	199.1 (s)	200.5 (s)	199.1 (s)	211.9 (s)	214.6 (s)	213.8 (s)	212.9 (s)
7	124.6 (d)	124.2 (d)	125.1 (d)	51.0 (t)	51.6 (t)	49.4 (t)	51.9 (t)
8	154.4 (s)	155.1 (s)	152.8 (s)	79.5 (s)	79.4 (s)	79.1 (s)	79.4 (s)
9	35.5 (t)	35.4 (t)	43.0 (t)	40.5 (t)	42.0 (t)	42.4 (t)	42.3 (t)
10	80.9 (d)	82.1 (d)	83.2 (d)	78.2 (d)	83.1 (d)	75.9 (d)	83.8 (d)
11	75.8 (d)	74.6 (d)	72.3 (d)	63.1 (d)	76.7 (d)	62.7 (d)	75.6 (d)
12	130.6 (s)	130.3 (s)	131.3 (s)	62.1 (s)	130.6 (s)	60.7 (s)	131.8 (s)
13	146.2 (d)	146.7 (d)	147.4 (d)	21.2 (t)	146.0 (d)	21.3 (t)	145.3 (d)
14	27.2 (t)	30.9 (t)	27.7 (t)	25.5 (t)	27.5 (t)	26.4 (t)	31.7 (t)
15	146.1 (s)	146.2 (s)	145.2 (s)	145.3 (s)	84.8 (s)	145.8 (s)	148.0 (s)
16	111.2 (t)	110.7 (t)	111.2 (t)	113.1 (t)	75.4 (t)	112.7 (t)	110.3 (t)
17	22.5 (q)	21.6 (q)	22.5 (q)	18.7 (q)	18.7 (q)	18.7 (q)	21.1 (q)
18	25.5 (q)	25.6 (q)	23.2 (q)	28.5 (q)	30.5 (q)	25.6 (q)	29.6 (q)
19	168.2 (s)	168.0 (s)	168.3 (s)	172.3 (s)	169.2 (s)	174.0 (s)	169.6 (s)
OEt	66.3 (t)	65.9 (t)	66.2 (t)				
	15.3 (q)	15.3 (q)	15.2 (q)				

<sup>a</sup> Spectra recorded at 125 MHz in  $\text{CDCl}_3$  at 25°C.

<sup>b</sup> Spectra recorded at 100 MHz in  $\text{CDCl}_3$  at 25°C.

<sup>c</sup> Spectra recorded at 75 MHz in  $\text{CDCl}_3$  at 25°C.

<sup>d</sup> Multiplicity deduced by DEPT and indicated by usual symbols. The values are in ppm downfield from TMS.

the above findings, **1** was thus suggested to be a bicyclic norditerpenoid possessing three olefinic bonds, one ester and two keto-carbonyl groups, one hydroxy group, and an ethoxy group. By comparison of the  $^{13}\text{C}$  NMR spectral data of **1** with those of **10**<sup>9</sup> (Table 1), a known metabolite also isolated in the present study, it was suggested that **1** has the same norcembrane carbon skeleton as that of **10** but with an additional trisubstituted double bond ( $\delta_{\text{C}}$  124.6, d and 154.4, s). The location of this double bond was established at C-7 and C-8 due to the downfield shift of H<sub>3</sub>-18 ( $\delta_{\text{H}}$  2.00, 3H, s) and the appearance of an additional vinylic proton at  $\delta_{\text{H}}$  6.45 (1H, s, H-7) in the  $^1\text{H}$  NMR spectrum of **1** (Table 2). This was further supported by the  $^1\text{H}/^{13}\text{C}$  long-range correlations observed in the HMBC spectrum (Fig. 2) between H<sub>3</sub>-18 and both C-8 ( $\delta_{\text{C}}$  154.4, s) and C-7 ( $\delta_{\text{C}}$  124.6, d), and between H-7 and the carbonyl carbon, C-6 ( $\delta_{\text{C}}$  199.1, s). The position of the ethoxy group at C-5 was also established through  $^1\text{H}/^{13}\text{C}$  long-range correlation observed between H-5 ( $\delta_{\text{H}}$  4.16, 1H, dd,  $J=10.0, 3.0$  Hz) and both the methylene carbon ( $\delta_{\text{C}}$  66.3, t) of the ethoxy group and C-6 carbonyl carbon. On the basis of the above observations, and by the assistance of a series of 2D NMR ( $^1\text{H}-^1\text{H}$  COSY, HMQC and HMBC) experiments, it was possible to establish the planar structure of **1**, as illustrated in Figure 2.

The relative stereochemistry of the four chiral centers at C-1, C-5, C-10, and C-11 in **1** was determined on the basis of the NOE correlations observed in a NOESY spectrum (Fig. 3), in addition to the chemical shifts and coupling constants of the concerned protons. The *Z*-geometry of the 7,8-double bond was established by the NOE interaction between H-7 ( $\delta_{\text{H}}$  6.45, s) and H<sub>3</sub>-18 ( $\delta_{\text{H}}$  2.00, s). One proton attaching at C-14 and resonating at  $\delta_{\text{H}}$  3.74 (ddd,  $J=15.5, 12.0, 4.0$  Hz) was found to show NOE interactions with H-1 ( $\delta_{\text{H}}$  2.85, br d,  $J=4.0$  Hz) and was assigned arbitrary as H-14 $\alpha$ . Thus, the isopropenyl group located at C-1 should be  $\beta$ -oriented. The other proton attaching at C-14, H-14 $\beta$




Figure 2.  $^1\text{H}-^1\text{H}$  COSY and HMBC correlations for **1**–**3** and **5**.

( $\delta_{\text{H}}$  2.25, dt,  $J=15.5, 4.0$  Hz), showed NOE interactions with the olefinic proton H-13 ( $\delta_{\text{H}}$  6.51, dd,  $J=12.0, 4.0$  Hz), confirming the upward orientation of H-13. The significant NOE interactions shown between oxymethine H-11 and olefinic H-13 revealed the parallel orientation of C<sub>11</sub>–H and C<sub>13</sub>–H, and hence, the *S*\* configuration at C-11 and the *cis* orientation of the 12,13-double bond, according to a molecular model represented in Figure 3. One H-9 ( $\delta_{\text{H}}$  3.53, dd,  $J=13.0, 9.5$  Hz) showed strong NOE correlation with H-11 and was assigned as H-9 $\alpha$ . Therefore, the significant NOE interaction observed between the other H-9 resonating at  $\delta_{\text{H}}$  2.48 (dd,  $J=13.0, 8.5$  Hz) and H-10 depicted the  $\beta$ -orientation of H-10, and hence the *R*\* configuration at C-10. The NOE interactions disclosed

Table 2.  $^1\text{H}$  NMR spectral data of compounds **1**–**5**

	<b>1</b> <sup>a</sup>	<b>2</b> <sup>a</sup>	<b>3</b> <sup>a</sup>	<b>4</b> <sup>b</sup>	<b>5</b> <sup>b</sup>
H-1	2.85 br d (4.0) <sup>c</sup>	2.77 br t (7.0)	2.97 dd (9.0, 4.5)	2.76 m	2.37 dt (8.0, 4.0)
H-2 $\alpha$	2.49 d (14.0)	2.52 dd (15.5, 7.0)	2.07 dd (17.0, 9.0)	2.58 dd (11.2, 2.8)	2.12 dd (14.0, 3.2)
H-2 $\beta$	2.86 d (14.0)	2.30 dd (15.5, 7.0)	2.27 dd (17.0, 4.5)	2.27 t (11.2)	1.94 dd (14.0, 8.0)
H-4 $\alpha$	2.85 dd (13.5, 10.0)	2.93 dd (16.0, 9.5)	3.06 dd (16.0, 3.0)	2.72 dd (14.2, 10.4)	1.84 dd (14.4, 11.6)
H-4 $\beta$	2.56 dd (13.5, 3.0)	2.80 dd (16.0, 2.5)	2.94 dd (16.0, 7.0)	2.63 dd (14.4, 2.4)	2.27 d (14.4, 1.5)
H-5	4.16 dd (10.0, 3.0)	4.03 dd (9.5, 2.5)	4.05 dd (7.0, 2.5)	4.46 dd (10.4, 2.0)	3.99 dd (11.5, 1.5)
H-7 $\alpha$	6.45 s	6.49 s	6.39 s	2.45 d (18.0)	2.39 d (18.4)
H-7 $\beta$				2.58 d (18.0)	2.49 d (18.4)
H-9 $\alpha$	3.53 dd (13.0, 9.5)	2.77 m	2.54 dd (14.0, 3.0)	2.14 dd (15.8, 2.6)	2.39 dd (14.2, 8.0)
H-9 $\beta$	2.48 dd (13.0, 8.5)	3.46 m	2.86 dd (14.0, 4.5)	2.38 dd (15.6, 4.4)	1.95 d (14.2)
H-10	4.69 dd (9.5, 8.5)	4.77 t (7.5)	4.73 br dd (4.5, 3.0)	4.72 dd (4.2, 3.0)	4.63 d (8.0)
H-11	4.51 s	4.50 s	4.63 s	4.14 s	4.47 s
H-13 $\alpha$				2.32 ddd (16.0, 10.8, 2.0)	
H-13 $\beta$	6.51 dd (12.0, 4.0)	6.51 dd (11.5, 6.0)	6.47 dd (12.0, 4.5)	1.88 ddd (16.0, 7.8, 2.2)	6.70 dd (12.4, 6.0)
H-14 $\alpha$	3.74 ddd (15.5, 12.0, 4.0)	3.55 m	3.53 ddd (14.0, 12.0, 4.5)	1.60 m	3.56 ddd (14.0, 12.4, 4.0)
H-14 $\beta$	2.25 dt (15.5, 4.0)	2.18 dt (13.5, 7.0)	2.22 dt (14.0, 4.5)	1.25 ddd (14.4, 10.8, 2.8)	2.27 dd (14.0, 6.0)
H-16	4.94 s	4.85 s	4.87 s	4.91 s	3.61 d (6.8) [ $\alpha$ ]
	4.75 s	4.72 s	4.53 s	4.80 s	3.39 d (6.8) [ $\beta$ ]
17-Me	1.83 3H, s	1.81 3H, s	1.81 3H, s	1.68 3H, s	1.59 3H, s
18-Me	2.00 3H, s	2.06 3H, s	2.27 3H, s	1.46 3H, s	1.62 3H, s
5-OEt	3.64 ddd (16.0, 7.0, 2.0)	3.55 dq (15.0, 7.0)	3.63 dq (15.0, 7.0)		
	3.59 ddd (16.0, 7.0, 2.0)	3.48 dq (15.0, 7.0)	3.55 dq (15.0, 7.0)		
	1.23 3H, t (7.0)	1.20 3H, t (6.5)	1.21 3H, t (7.0)		

<sup>a</sup> Spectra recorded at 500 MHz in  $\text{CDCl}_3$  at 25°C.

<sup>b</sup> Spectra recorded at 400 MHz in  $\text{CDCl}_3$  at 25°C.

<sup>c</sup> The *J* values are in Hz in parentheses.




Figure 3. Key NOESY correlations of **1**, **2**, and **3**.

between both H-10 and H-9 $\beta$  and H<sub>3</sub>-18, H<sub>3</sub>-18 and H-7, and H-7 and H-5, revealed that H-5 is positioned on the upward face of the fourteen-membered ring as shown in Figure 3 and is *syn* oriented relative to H-10. On the basis of the above findings and other key NOE interactions observed (see Fig. 3), the structure of leptocladolide A (**1**), was unambiguously established as shown in formula 1.

The new metabolite, 1-*epi*-leptocladolide (**2**), also isolated from *S. parva*, was obtained as colorless oil. On the basis of its HRFABMS ( $m/z$  377.1966, [M+H]<sup>+</sup>), along with the <sup>1</sup>H and <sup>13</sup>C NMR spectral data, the molecular formula of **2** was established as C<sub>21</sub>H<sub>28</sub>O<sub>6</sub>. As in the case of **1**, **2** also revealed the presence of a hydroxy group (EIMS  $m/z$  358 [M-H<sub>2</sub>O]<sup>+</sup>, IR  $\nu_{\max}$  3414 cm<sup>-1</sup>) and an ethoxy group (EIMS  $m/z$  330 [M-EtOH]<sup>+</sup>). Furthermore, it was found that the <sup>1</sup>H and <sup>13</sup>C NMR spectral data of **2** were very similar to those of leptocladolide A (**1**) (Tables 1 and 2), suggesting that **2** could be an epimer of **1**. By the assistance of 2D NMR spectra, including COSY, HMQC, and HMBC, **2** was shown to possess the same molecular framework as that of **1** (Fig. 2). However, the significant downfield shifts for C-1 ( $\Delta\delta_C$  +3.2 ppm), C-2 ( $\Delta\delta_C$  +1.4 ppm) and C-14 ( $\Delta\delta_C$  +3.7 ppm) in comparison with those of **1** (Table 1), suggesting that **2** might be the C-1 epimer of **1**. By careful investigation on the NOESY spectrum of **2** (Fig. 3), it was found that H-1 showed significant NOE interactions with H<sub>2</sub>-2 and H-14 $\beta$  ( $\delta_H$  2.18, 1H, dt,  $J=13.5, 7.0$  Hz), revealing the  $\beta$ -orientation of H-1 and thus the *R*<sup>\*</sup> configuration at C-1. Further analyses on other NOE interactions revealed that **2** possessed the same relative configurations at C-5, C-10, and C-11, as those of **1** (Fig. 3). Therefore, **2** was found to be the C-1 epimer of **1** and the structure of this new metabolite could be established as described by formula 2.

The third related new norditerpenoid isolated from *S. parva*, 7*E*-leptocladolide A (**3**), has the same molecular formula C<sub>21</sub>H<sub>28</sub>O<sub>6</sub> and was considered to be an isomer of **1** and **2** on the basis of HREIMS and NMR spectral data (Tables 1 and 2). Also, spectral data revealed the presence of a hydroxy group (IR  $\nu_{\max}$  3429 cm<sup>-1</sup>, EIMS  $m/z$  358 [M-H<sub>2</sub>O]<sup>+</sup>) and an ethoxy group (IR EIMS  $m/z$  330 [M-EtOH]<sup>+</sup>) in **3**. In general, the <sup>1</sup>H and <sup>13</sup>C NMR data of **3** were found to be similar to those of **1** and **2**. Nevertheless,  $\delta_C$  of C-1 and C-14 of **3** were more or less close to those of **1** in comparison with those of **2** (Table 1), suggesting that the relative configuration at C-1 is possibly the same as that of **1**. Moreover, the

upfield shifts observed for C-8 ( $\Delta\delta_C$  -2.3–1.6 ppm) and C-18 ( $\Delta\delta_C$  -2.4–2.3 ppm), and the downfield shift of C-9 ( $\Delta\delta_C$  +7.6–7.5 ppm) in comparison with those of **1** and **2** (Table 1), suggested that **3** could possess different geometry for the 7,8-carbon, carbon double bond, in contrast to those of **1** and **2**. According to the NOESY spectrum of **3** (Fig. 3), H-7 did not show NOE response with H<sub>3</sub>-18, confirming the *E*-geometry of 7,8-double bond. Furthermore, it was found that the relative stereochemistry of C-1 in **3** is similar to that of **1** on the basis of NOE correlations observed between H-1 ( $\delta_H$  2.97, 1H, dd,  $J=9.0, 4.5$  Hz) and H<sub>2</sub>-14, and between olefinic H-16 ( $\delta_H$  4.53, s) and those of olefinic H-13 ( $\delta_H$  6.47, dd,  $J=12.0, 4.5$  Hz) and H<sub>2</sub>-2. The significant interaction exhibited between oxymethine H-11 and olefinic proton H-13 again revealed the *S*<sup>\*</sup> configuration at C-11, the same as that in **1**. By consideration of the above findings, along with other NOE responses observed as shown in Figure 3, the structure of compound **3** was unambiguously established as 7*E*-leptocladolide A.

The new norditerpenoid metabolite leptocladolide B (**4**) was isolated from *S. leptocladus* as a white solid. Its EIMS ( $m/z$  384 [M]<sup>+</sup>) and <sup>13</sup>C NMR spectral data, including those of DEPT (Table 1), established a molecular formula C<sub>19</sub>H<sub>24</sub>O<sub>6</sub> and eight degrees of unsaturation. The <sup>13</sup>C NMR data of **4** showed signals of 19 carbon atoms, including those of an 1,1-disubstituted double bond ( $\delta_C$  113.1, t and 145.3, s), one ester and two ketone carbonyl groups ( $\delta_C$  172.3, s, 208.4, s, and 211.9, s, respectively). Interpretation of <sup>1</sup>H and <sup>13</sup>C NMR spectral data (Tables 1 and 2), by the assistance of 2D NMR spectra, revealed that **4** possesses a trisubstituted oxotetrahydrofuran moiety [<sup>1</sup>H NMR  $\delta_H$  4.46 (1H, dd,  $J=10.4, 2.0$  Hz); <sup>13</sup>C NMR  $\delta_C$  211.9 (s), 79.5 (s), and 78.1 (d)], a  $\gamma$ -lactone group with a trisubstituted epoxide [<sup>1</sup>H NMR  $\delta_H$  4.14 (1H, s) and 4.72 (1H, dd,  $J=4.4, 3.0$  Hz); <sup>13</sup>C NMR  $\delta_C$  172.3 (s), 78.2 (d), 63.1 (d), and 62.1 (s)]. These observations revealed that the structure of **4** should be similar to that of scabrolide D (**6**), previously isolated from *S. scabra*<sup>16</sup> (Table 1). Therefore, compound **4** was suggested to be a stereoisomer of **6**. Careful investigation on NOESY spectrum of **4**, in comparison with that of **6**, could be useful for determination of the relative stereochemistry of **4** (Fig. 5). Assuming the  $\alpha$ -orientation of H<sub>3</sub>-18, it was found that H<sub>3</sub>-18 exhibited NOE correlations with H-7 $\alpha$  ( $\delta_H$  2.45, d,  $J=18.0$  Hz), H-9 $\alpha$  ( $\delta_H$  2.14, dd,  $J=15.8, 2.6$  Hz), and H-4 $\alpha$  ( $\delta_H$  2.72, dd,  $J=14.2, 10.4$  Hz), but not with H-4 $\beta$  ( $\delta_H$  2.63, dd,  $J=14.4, 2.4$  Hz) or H-5 ( $\delta_H$



4.46, dd,  $J=10.4$ , 2.0 Hz). However, significant NOE interactions between H-5 and H-4 $\beta$  were observed, indicating the  $\beta$ -orientation of H-5. Thus, C-5 is  $S^*$  configured. Moreover, the downfield shifts observed at C-5 ( $\Delta\delta_C +2.9$  ppm) and C-18 ( $\Delta\delta_C +2.9$  ppm) and the upfield shift at C-6 ( $\Delta\delta_C -1.9$  ppm) relative to those of **6** were considered as additional evidences for the  $5S^*$  configuration<sup>9,10,16</sup> in **4**, in contrast to **6**<sup>16</sup> and other  $5R^*$ -related norcembranoids.<sup>3,8–10</sup> H-1 was found to exhibit NOE response with H<sub>3</sub>-18, suggesting the  $\beta$ -orientation of the isopropenyl group at C-1. The methyl protons, H<sub>3</sub>-16, showed NOE responses with H-2 $\beta$  ( $\delta_H$  2.27, t,  $J=11.2$  Hz) and H-14 $\beta$  ( $\delta_H$  1.25, ddd,  $J=14.4$ , 10.8, 2.8 Hz), but not with H-14 $\alpha$  ( $\delta_H$  1.60, m), which in turn correlated with H-11 ( $\delta_H$  4.14, s), and revealing the  $\alpha$ -orientation of H-11. H-11 did not show NOE response with H-10, and revealing the  $\beta$ -orientation of H-10. Thus, the relative structure of **4** was fully established.

A novel norcembranoid leptocladolide C (**5**), isolated from *S. leptocladus*, was obtained as a white solid. Its HREIMS ( $m/z$  364.1519,  $M^+$ ) and the  $^1H$ , and  $^{13}C$  NMR spectral data, suggested a molecular formula of  $C_{19}H_{24}O_7$ , consistent with eight degrees of unsaturation. A hydroxy group was suggested to be present in **5** (EIMS,  $m/z$  346  $[M-H_2O]^+$  and IR  $\nu_{max}$  3424  $cm^{-1}$ ). The  $^{13}C$  NMR spectrum displayed nineteen carbon signals which were assigned into two methyls, six methylenes including an oxygenated one ( $\delta_C$  75.4, t), five methines including three oxygenated and one vinylic ( $\delta_C$  83.1, d, 77.3, d, 76.7, d and 146.0, d, respectively), and six quaternary carbons including one oxygenated ( $\delta_C$  79.4, s) and one dioxygenated ( $\delta_C$  108.7, s). The carbon signals appearing at  $\delta_C$  214.6 (s), 169.2 (s), 146.0 (d), and 130.6 (s) indicated the presence of a normal ketone, and an  $\alpha,\beta$ -conjugated ester in **5**. Therefore, metabolite **5** is a pentacyclic norcembranoid. The  $^1H$  NMR of **5** (Table 2) showed two 3H singlets at  $\delta_H$  1.62 and 1.59 which were attributed to two tertiary methyl groups, three 1H signals at  $\delta_H$  4.63 (d,  $J=8.0$  Hz), 4.47 (s), and 3.99 (dd,  $J=11.5$ , 1.5 Hz) ascribable to three oxymethine groups, two 1H doublets at  $\delta_H$  3.61 (d,  $J=6.8$  Hz) and 3.39 (d,  $J=6.8$  Hz) of an oxymethylene group, and the signal of a vinylic proton of a trisubstituted double bond ( $\delta_H$  6.70, dd,  $J=12.4$ , 6.0 Hz). Comparison of the  $^{13}C$  NMR spectral data of **5** with those of sinuleptolide **10**<sup>9</sup> (Table 1) revealed that **5** should possess the same partial structure extending from C-4 to C-14 as **10**, while the signals of C-3 carbonyl carbon ( $\delta$  208.2, s) and 1,1-disubstituted double bond of the isopropenyl group ( $\delta_C$  148.0, s and 110.3, t) of **10** disappeared and were replaced by carbon signals resonating at  $\delta_C$  108.7 (s), 84.8 (s), and 75.4 (t), respectively. These results suggested that C-3 carbonyl has been transformed into a ketal with two oxygen atoms further connected with C-15 and C-16, respectively, to furnish tetrahydrofuran and tetrahydropyran rings. After investigating the  $^1H$ - $^1H$  COSY spectrum of **5**, it was possible to establish the sequential proton sets extending from H<sub>2</sub>-4 to H-5, H-9 to H-11, and H-13 to H<sub>2</sub>-2 through H-1 (Fig. 4). In the HMBC spectrum of **5**, it was found that H<sub>3</sub>-17 ( $\delta$  1.59, 3H, s) exhibited long-range  $^1H/^{13}C$  correlations with C-16 ( $\delta_C$  75.4, t), C-1 ( $\delta_C$  44.4, d), and C-15 ( $\delta_C$  84.8, s), indicating that this ring-junctured methyl group should be located at C-15. According to the above




Figure 4.  $^1H$ - $^1H$  COSY and HMBC correlations for **5**.

observations and by careful analysis of HMBC spectrum with the aid of HMQC spectral data, the framework of **5** could be established as shown in Figure 4. The relative stereochemistry of **5** was deduced by careful study of the NOESY spectrum. As in the case of **4**, it was found that the  $\alpha$ -oriented H<sub>3</sub>-18 did not exhibit NOE response with H-5, indicating the  $S^*$  configuration of C-5. This was further confirmed by the diagnostic chemical shifts of C-5, C-6, and C-18 which are similar to those of  $5S^*$ -related norcembranoids as in cases of **4** and **10**. One proton of H<sub>2</sub>-2 resonating at  $\delta_H$  1.94 (1H, dd,  $J=14.0$ , 8.0 Hz) showed significant NOE interaction with H-5, and was assigned as H-2 $\beta$ . The other proton, H-2 $\alpha$  ( $\delta_H$  2.12, dd,  $J=14.0$ , 3.2 Hz), exhibited NOE correlation with H-14 $\alpha$  ( $\delta_H$  3.56, ddd,  $J=14.0$ , 12.4, 4.0 Hz), which further correlated with H-1, and revealing the  $\alpha$ -orientation of H-1. The protons of the ring-junctured methyl, H<sub>3</sub>-17, exhibited marked NOE correlation with H-1, implying the  $\alpha$ -orientation of the methyl substituent at C-15. One oxymethylene proton, H-16 $\alpha$ , showed significant correlation with H-1, suggesting that the oxymethylene moiety of the




Figure 5. Key NOESY correlations for **4** and **5**.

tetrahydropyran attached at C-3 should be  $\alpha$ -oriented. Furthermore, H-11 exhibited significant correlation with H-13 and H-10, revealing the  $\beta$ -orientation of H-10 and  $\alpha$ -orientation of H-11, as those in **1–3**. From the above findings and other correlations observed (Fig. 5), the structure of leptocladolide C was unambiguously established as in formula **5**.

It is worthwhile to mention that the new metabolites **1–3** represent a new class of bicyclic norcembrane-based diterpenoids lacking 5,8-ether linkages. Also, **5** was found to contain a novel 2,7-dioxa-bicyclo[2,2,1]heptane structural unit, which has not been found previously in diterpenoids, to the best of our knowledge.

Other known compounds **6–10**, which were also isolated from *S. leptocladus*, were found to be identical with the previously reported scabrolide D (**6**) and scabrolide A (**8**)<sup>16</sup> isolated from *S. scabra*, ineleganolide (**7**)<sup>8</sup> from *S. inelegans*, norcembranoid **9** from *S. leptocladus*,<sup>1</sup> *S. polydactyla*<sup>17</sup> and *S. scabra*,<sup>16</sup> and sinuleptolide **10** isolated from an unidentified *Sinularia* species<sup>9</sup> by comparison of the physical (mp and  $[\alpha]_D$ ) and spectral (MS, <sup>1</sup>H and <sup>13</sup>C NMR) data. Although **9** was the first 5*R*\*,11*S*\*-norcembranoid discovered,<sup>1,3,4,9,17</sup> as confirmed by single-crystal X-ray analyses,<sup>1,17</sup> it was misleadingly configured occasionally as an 5*R*\*,11*R*\*-epimer (**11**).<sup>1,17</sup> This contradiction prompted us to reinvestigate the <sup>1</sup>H and <sup>13</sup>C NMR spectral data of **9** in CDCl<sub>3</sub> and pyridine-*d*<sub>5</sub>. It was found that the spectral data in CDCl<sub>3</sub> are in full agreement with those published by Bowden et al.<sup>1</sup> and Duh et al.,<sup>17</sup> who represented **9** incorrectly as an 5*R*\*,11*R*\*-epimer. Moreover, the NMR spectral data of **9** in pyridine-*d*<sub>5</sub> were found to be superimposable to those published by Shoji et al.,<sup>9</sup> where it was presented as the 5*R*\*,11*S*\*-epimer. Thus, the structure of **11**, shown in Refs. 1,16,17, should be revised as **9**. Furthermore, the NMR spectra of **10**, isolated in the present study and previously published as **9** by our group,<sup>16</sup> were remeasured in pyridine-*d*<sub>5</sub> and gave data (see Section 3) which are nicely fitted with those of sinuleptolide (5*S*\*,11*S*\*-epimer, **10**).<sup>9</sup> Thus, the relative configuration of this metabolite should also be revised as that of **10**. On the basis of all above findings, we can conclude that metabolite **11** has not been discovered yet.

Our previous study revealed strong cytotoxic activity for the tricyclic norcembranoids **9** and **10** against the growth of KB and Hepa59T/VGH cancer cells (ED<sub>50</sub> 2.3–2.6  $\mu$ g/mL).<sup>16</sup> This result prompted us to extend our study on biological activity of the related norcembranoids. The cytotoxicity of metabolites **1–8** was thus evaluated on the same cell lines. It was found that the new metabolites **4** and **5** and the known compounds (**6–8**) were inactive (ED<sub>50</sub> >20  $\mu$ g/mL) against the growth of both cells, while the three new bicyclic norcembranoids (**1–3**) exhibited variable activity. Leptocladolide A (**1**) exhibited significant cytotoxicity against KB and Hepa59T/VGH cells lines with ED<sub>50</sub> of 5.9 and 2.6  $\mu$ g/mL, respectively, while 7*E*-leptocladolide A (**3**) was found to be more cytotoxic against Hepa59T/VGH cells (ED<sub>50</sub> 3.2  $\mu$ g/mL) relative to KB cells (ED<sub>50</sub> 12.0  $\mu$ g/mL). The related C-1 epimeric metabolite **2** showed only weak cytotoxic activity against both cell lines (ED<sub>50</sub> 15.1 and 14.5  $\mu$ g/mL, respectively).

### 3. Experimental

#### 3.1. General experimental procedures

Melting points were determined using a Fisher–Johns melting point apparatus. Optical rotations were measured on a Jasco DIP-1000 digital polarimeter. IR spectra were recorded on a Jasco FT-5300 infrared spectrophotometer. EIMS was obtained with a VG Quattro GC/MS spectrometer. HRMS spectra were recorded on a Finnigan MAT-95XL mass spectrometer. The NMR spectra were recorded on a Bruker AVANCE DPX300 FT NMR at 300 MHz for <sup>1</sup>H and 75 MHz for <sup>13</sup>C or on Bruker AMX-400 FT NMR at 400 MHz for <sup>1</sup>H and 100 MHz for <sup>13</sup>C or on a Varian Unity INOVA 500 FT NMR at 500 MHz for <sup>1</sup>H and 125 MHz for <sup>13</sup>C, respectively, in CDCl<sub>3</sub> using TMS as internal standard, unless otherwise indicated. Si gel (Merck, 230–400 mesh) was used for column chromatography. Precoated Si gel plates (Merck, Kieselgel 60 F-254, 0.2 mm) were used for analytical TLC.

#### 3.2. Organism

*S. leptocladus* and *S. parva* were collected by hand via SCUBA at the coast of Kenting, Taiwan in February, 2000 and in December, 2001, respectively, at a depth of 15–20 m, and stored in a freezer until extraction. A voucher samples was deposited at the Department of Marine Resources, National Sun Yat-Sen University (specimens no. SC01 for *S. leptocladus* and SC 36 for *S. parva*).

#### 3.3. Extraction and separation

The sliced bodies of *S. leptocladus* (724 g, wet wt) were homogenized with EtOAc and filtered. The organic layers were combined and concentrated under vacuum to afford a dark brown viscous residue (23.4 g). The residue was triturated with *n*-hexane first to afford *n*-hexane soluble layer, and then with dichloromethane. The dichloromethane soluble layer was evaporated under reduced pressure to afford a residue (4.1 g) which was subjected to column chromatography on silica gel, using *n*-hexane, *n*-hexane and EtOAc mixture of increasing polarity, and finally pure EtOAc, to yield 35 fractions. Fractions 21 and 24 eluted with *n*-hexane–EtOAc (2:1), were further purified on silica gel using *n*-hexane–EtOAc (gradient, 2:1–1:1) to yield **4** (1.9 mg) and **6** (4.1 mg) from fraction 21, and **7** (5.7 mg) from fraction 24, respectively. Fractions 26 and 27 eluted with *n*-hexane–EtOAc (1:1), were purified separately by normal phase HPLC using *n*-hexane–EtOAc (1:1) to afford **1** (1.3 mg) from fraction 26 and **8** (3.4) from fraction 27, respectively. Fraction 28 eluted with *n*-hexane–EtOAc (1:1), was further chromatographed over silica gel using *n*-hexane–acetone (5:1) to furnish **10** (344.2 mg) and a mixture, which was further purified by normal phase HPLC using *n*-hexane–EtOAc (9:11) to afford **9** (304.5 mg) and **5** (11.2 mg), respectively.

The tissues of *S. parva* (200 g, wet wt) were exhaustively extracted with EtOH. The alcoholic extract was concentrated under vacuum to afford a dark brown residue. The residue was triturated with *n*-hexane and then triturated further with dichloromethane. The dichloromethane was

concentrated to afford a residue (0.82 g), which primarily fractionated over silica gel, using the same solvent systems as described above to yield 15 fractions. Fractions 11 and 12 eluted with *n*-hexane–EtOAc (1:1) was further isolated and purified by normal phase HPLC, using *n*-hexane–EtOAc (1:1) to yield **2** (1.2 mg) and **7** (2.3 mg) from fraction 11, and **1** (0.8 mg), and **3** (1.1 mg) from fraction 12.

**3.3.1. Leptocladolide A (1).** Colorless oil,  $[\alpha]_{\text{D}}^{25} = -33.3^\circ$  (*c* 0.24, CHCl<sub>3</sub>); IR (neat)  $\nu_{\text{max}}$  3420, 2975, 2361, 2361, 1750, 1700, 1680, 1614, 1445, 1381, 1175, 1098 cm<sup>-1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz) and <sup>13</sup>C NMR (CDCl<sub>3</sub>, 125 MHz), see Tables 1 and 2, respectively; FABMS *m/z* 377 (0.8, [M+H]<sup>+</sup>), 359 (0.5, [M+H–H<sub>2</sub>O]<sup>+</sup>), 331 (0.6, [M+H–EtOH]<sup>+</sup>), 307 (7.9, [M+H–C<sub>2</sub>H<sub>5</sub>–C<sub>3</sub>H<sub>5</sub>]<sup>+</sup>), 289 (6.3, [M–EtOH–C<sub>3</sub>H<sub>5</sub>]<sup>+</sup> or [M+H–C<sub>2</sub>H<sub>5</sub>–C<sub>3</sub>H<sub>5</sub>–H<sub>2</sub>O]<sup>+</sup>), 154 (100.0); HRFABMS *m/z* 377.1964 (calcd for C<sub>21</sub>H<sub>29</sub>O<sub>6</sub>, 377.1965).

**3.3.2. 1-epi-Leptocladolide A (2).** Colorless oil,  $[\alpha]_{\text{D}}^{29} = -55.0^\circ$  (*c* 0.40, CHCl<sub>3</sub>); IR (neat)  $\nu_{\text{max}}$  3414, 2922, 2361, 1751, 1726, 1711, 1611, 1381, 1095 cm<sup>-1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz) and <sup>13</sup>C NMR (CDCl<sub>3</sub>, 125 MHz), see Tables 1 and 2, respectively; EIMS (70 eV) *m/z* 376 (1.4, [M]<sup>+</sup>), 358 (1.3, [M–H<sub>2</sub>O]<sup>+</sup>), 330 (4.2, [M–EtOH]<sup>+</sup>), 313 (2.1, [M+H–EtOH–H<sub>2</sub>O]<sup>+</sup>), 167 (52.5), 109 (46.9); FABMS *m/z* 377 (0.9, [M+H]<sup>+</sup>), 359 (0.5, [M+H–H<sub>2</sub>O]<sup>+</sup>), 331 (0.9, [M+H–EtOH]<sup>+</sup>), 307 (0.9, [M+H–C<sub>2</sub>H<sub>5</sub>–C<sub>3</sub>H<sub>5</sub>]<sup>+</sup>), 289 (1.3, [M–EtOH–C<sub>3</sub>H<sub>5</sub>]<sup>+</sup> or [M+H–C<sub>2</sub>H<sub>5</sub>–C<sub>3</sub>H<sub>5</sub>–H<sub>2</sub>O]<sup>+</sup>), 154 (55); HRFABMS *m/z* 377.1966 (calcd for C<sub>21</sub>H<sub>29</sub>O<sub>6</sub>, 377.1965).

**3.3.3. 7E-Leptocladolide A (3).** Colorless oil,  $[\alpha]_{\text{D}}^{29} = -63.5^\circ$  (*c* 0.52, CHCl<sub>3</sub>); IR (neat)  $\nu_{\text{max}}$  3429, 2974, 2924, 2361, 1750, 1707, 1690, 1614, 1379, 1092 cm<sup>-1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz) and <sup>13</sup>C NMR (CDCl<sub>3</sub>, 125 MHz), see Tables 1 and 2, respectively; EIMS (30 eV) *m/z* 376 (0.2, [M]<sup>+</sup>), 358 (0.3, [M–H<sub>2</sub>O]<sup>+</sup>), 330 (0.6, [M–EtOH]<sup>+</sup>), 313 (0.8, [M+H–EtOH–H<sub>2</sub>O]<sup>+</sup>), 193 (8.6), 167 (39.4); HREIMS *m/z* 376.1871 (calcd for C<sub>21</sub>H<sub>28</sub>O<sub>6</sub>, 376.1880).

**3.3.4. Leptocladolide B (4).** White solid, mp 172–173°;  $[\alpha]_{\text{D}}^{25} = +10.0^\circ$  (*c* 0.24, CHCl<sub>3</sub>); IR (neat)  $\nu_{\text{max}}$  2930, 1775, 1761, 1705, 1385, 1090 cm<sup>-1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) and <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz), see Tables 1 and 2, respectively; EIMS (70 eV) *m/z* 348 (8.0, [M]<sup>+</sup>), 298 (4.2), 149 (23.8), 134 (53.5), 109 (34.6).

**3.3.5. Leptocladolide C (5).** White solid, mp 215–216°;  $[\alpha]_{\text{D}}^{25} = +83.0^\circ$  (*c* 0.30, CHCl<sub>3</sub>); IR (neat)  $\nu_{\text{max}}$  3424, 3017, 2924, 1757, 1674, 1585, 1443, 1379, 1186, 1096 cm<sup>-1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) and <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz), see Tables 1 and 2, respectively; EIMS (70 eV) *m/z* 365 (22.0, [M+H]<sup>+</sup>), 364 (100.0, [M]<sup>+</sup>), 347 (24.0, [M+H–H<sub>2</sub>O]<sup>+</sup>), 346 (4.7, [M–H<sub>2</sub>O]<sup>+</sup>), 157 (45), 109 (27); HREIMS *m/z* 364.1519 (calcd for C<sub>19</sub>H<sub>24</sub>O<sub>7</sub>, 364.1522).

**3.3.6. Scabrolide D (6).** White solid, mp 83–84°;  $[\alpha]_{\text{D}}^{25} = -58.3^\circ$  (*c* 0.24, CHCl<sub>3</sub>); IR (neat)  $\nu_{\text{max}}$  2932, 1761, 1751, 1666, 1381, 1090 cm<sup>-1</sup>; MS; <sup>1</sup>H and <sup>13</sup>C NMR spectral data were found to be in full agreement with those reported previously.<sup>16</sup>

**3.3.7. Ineleganolide (7).** White solid, mp 187–189°;  $[\alpha]_{\text{D}}^{25} = +48.5^\circ$  (*c* 0.68, CHCl<sub>3</sub>) [lit.,<sup>8</sup> +26.4° (*c* 0.05, CHCl<sub>3</sub>)]; IR (neat)  $\nu_{\text{max}}$  2966, 1757, 1707, 1645, 1377, 1321, 1217, 1170, 1067, 1024 cm<sup>-1</sup>; EIMS (70 eV) *m/z* 330 (21.4, [M]<sup>+</sup>), 215 (7.6), 164 (15.9), 135 (23.6), 121 (24.4), 105 (23.8); IR, MS, <sup>1</sup>H and <sup>13</sup>C NMR spectral data were found to be in full agreement with those reported previously.<sup>8</sup>

**3.3.8. Scabrolide A (8).** White solid, mp 92–93°;  $[\alpha]_{\text{D}}^{29} = -104.0^\circ$  (*c* 0.48, CHCl<sub>3</sub>); IR (neat)  $\nu_{\text{max}}$  3462, 2920, 2361, 2338, 1757, 1699, 1651, 1373, 1088 cm<sup>-1</sup>; MS; <sup>1</sup>H and <sup>13</sup>C NMR spectral data were found to be in full agreement with those reported previously.<sup>16</sup>

**3.3.9. Norcembranoid 9.** Colorless needles, mp 226–227°;  $[\alpha]_{\text{D}}^{25} = -119.0^\circ$  (*c* 0.16, CHCl<sub>3</sub>); IR (neat)  $\nu_{\text{max}}$  3684, 3029, 2942, 1757, 1715, 1674, 1207, 1180, 1099 cm<sup>-1</sup>; <sup>1</sup>H NMR (Pyridine-*d*<sub>5</sub>, 300 MHz),  $\delta$  6.62 (1H, dd, *J*=11.1, 3.7 Hz, H-13), 4.96 (1H, s, H-11), 4.95 (1H, d, *J*=8.0 Hz, H-10), 4.78 (1H, s, H-16), 4.77 (1H, s, H-16), 4.55 (1H, dd, *J*=9.6, 2.7 Hz, H-5), 4.19 (1H, ddd, *J*=15.6, 11.1, 6.3 Hz, H-14), 3.04 (1H, m, H-1), 2.84 (1H, dd, *J*=15.9, 2.8 Hz, H-4), 2.82 (1H, m, H-2), 2.80 (1H, m, H-4), 2.52 (1H, d, *J*=16.5 Hz, H-7), 2.46 (1H, d, *J*=16.5 Hz, H-7), 2.46 (1H, m, H-2), 2.44 (1H, m, H-9), 2.20 (1H, br d, *J*=11.0 Hz, H-14), 2.18 (1H, d, *J*=13.8 Hz, H-9), 1.65 (3H, s, H<sub>3</sub>-17), 1.41 (3H, s, H<sub>3</sub>-18); <sup>13</sup>C NMR (pyridine-*d*<sub>5</sub>, 75 MHz),  $\delta$  215.0 (C-6), 205.6 (C-3), 169.5 (C-19), 147.6 (C-15), 142.7 (C-13), 134.2 (C-12), 110.3 (C-16), 84.3 (C-10), 79.3 (C-8), 75.6 (2C, C-5, C-11), 51.5 (C-7), 45.6 (C-2), 43.8 (C-4), 42.8 (C-9), 39.4 (C-1), 27.9 (C-14), 25.9 (C-18), 21.7 (C-17); IR, MS; <sup>1</sup>H and <sup>13</sup>C NMR spectral data were found to be in full agreement with those reported previously.<sup>1,17</sup>

**3.3.10. Sinuleptolide (10).** White powder, mp 193–194°;  $[\alpha]_{\text{D}}^{25} = +62.5^\circ$  (*c* 0.08, CHCl<sub>3</sub>); IR (neat)  $\nu_{\text{max}}$  3688, 3023, 2940, 2361, 1757, 1713, 1672, 1217, 1180, 1097 cm<sup>-1</sup>; MS; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz),  $\delta$  6.52 (1H, dd, *J*=10.8, 6.1 Hz, H-13), 4.86 (1H, s, H-16), 4.80 (1H, s, H-16), 4.65 (1H, d, *J*=6.6 Hz, H-10), 4.61 (1H, s, H-11), 4.39 (1H, dd, *J*=9.1, 3.7 Hz, H-5), 3.71 (1H, ddd, *J*=13.5, 10.5, 4.5 Hz, H-14), 2.82 (1H, m, H-1), 2.67 (1H, d, *J*=13.8 Hz, H-2), 2.63–2.54 (2H, m, H<sub>2</sub>-4), 2.54 (2H, m, H-2, H-7), 2.41 (1H, d, *J*=17.0 Hz, H-7), 2.39 (1H, dd, *J*=15.0, 4.0 Hz, H-9), 2.16 (1H, dt, *J*=13.5, 7.0 Hz, H-14), 2.05 (1H, d, *J*=15.0 Hz, H-9), 1.83 (3H, s, H<sub>3</sub>-17), 1.49 (3H, s, H<sub>3</sub>-18); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz), see Table 1; <sup>1</sup>H NMR (Pyridine-*d*<sub>5</sub>, 300 MHz),  $\delta$  6.65 (1H, dd, *J*=11.1, 4.5 Hz, H-13), 4.99 (1H, d, *J*=7.6 Hz, H-10), 4.92 (1H, s, H-11), 4.81 (1H, s, H-16), 4.77 (1H, s, H-16), 4.67 (1H, dd, *J*=11.1, 1.5 Hz, H-5), 4.13 (1H, ddd, *J*=13.5, 10.1, 3.6 Hz, H-14), 2.98 (1H, m, H-1), 2.90 (1H, dd, *J*=13.8, 2.0 Hz, H-2), 2.89 (1H, t, *J*=14.8 Hz, H-4), 2.59 (1H, d, *J*=18.0 Hz, H-7), 2.57 (1H, m, H-2), 2.48 (1H, d, *J*=18.0 Hz, H-7), 2.34 (1H, dd, *J*=15.5, 7.5 Hz, H-9), 2.15 (1H, d, *J*=15.5 Hz, H-9), 2.20 (1H, m, H-14), 1.70 (3H, s, H<sub>3</sub>-17), 1.59 (3H, s, H<sub>3</sub>-18); <sup>13</sup>C NMR (Pyridine-*d*<sub>5</sub>, 75 MHz),  $\delta$  213.9 (C-6), 206.7 (C-3), 169.8 (C-19), 147.8 (C-15), 142.7 (C-13), 133.5 (C-12), 110.4 (C-16), 84.7 (C-10), 79.8 (C-8), 77.3 (C-5), 76.0 (C-11), 51.4 (C-7), 46.1 (C-2), 44.6 (C-4), 41.6 (C-9), 40.0 (C-1), 29.5 (C-14), 29.5 (C-18), 21.6 (C-17); EIMS (70 eV) *m/z* 348 (8.0, [M]<sup>+</sup>), 298 (4.2), 149 (23.8), 134 (53.5), 109

(34.6); IR, MS spectral data were found to be in full agreement with those reported previously.<sup>9</sup>

### 3.4. Cytotoxicity testing

Hepa59T/VGH and KB cells were purchased from the American Type Culture Collection (ATCC). Cytotoxicity assays of the test compounds **3–8** were performed using MTT [3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyltetrazolium bromide] colorimetric method.<sup>18,19</sup>

### Acknowledgements

This work was supported by a grant from the National Science Council of the Republic of China (Contract No. NSC-90-2323-B-110-003) awarded to J.-H.S.

### References

- Bowden, B. F.; Coll, J. C.; Mitchell, S. J.; Mulden, J.; Stokie, G. *J. Aust. J. Chem.* **1978**, *31*, 2049–2056.
- Faulkner, D. *J. Nat. Prod. Rep.* **2003**, *20*, 1–48, and previous reports of this series.
- Sato, A.; Fenical, W.; Qi-tai, Z.; Clardy, J. *Tetrahedron* **1985**, *41*, 4303–4308.
- Kobayashi, M.; Rao, K. M. Ch. A.; Krishna, M. M.; Anjaneyulu, V. *J. Chem. Res. (S)* **1995**, 188–189.
- Ramesh, P.; Venkateswarlu, Y. *J. Chem. Res. (S)* **2000**, 48–50.
- Iguchi, K.; Kajiyama, K.; Yamada, Y. *Tetrahedron Lett.* **1995**, *36*, 8807–8808.
- Iguchi, K.; Kajiyama, K.; Miyaoka, H.; Yamada, Y. *J. Org. Chem.* **1996**, *61*, 5998–6000.
- Duh, C.-Y.; Wang, S.-K.; Chia, M.-C.; Chiang, M. Y. *Tetrahedron Lett.* **1999**, *40*, 6033–6035.
- Shoji, N.; Umeyama, A.; Arihara, S. *J. Nat. Prod.* **1993**, *56*, 1651–1653.
- El Sayed, K. A.; Hamann, M. T. *J. Nat. Prod.* **1996**, *59*, 687–689.
- Sheu, J.-H.; Sung, P.-J.; Huang, L.-H.; Lee, S.-F.; Wu, T.; Chang, B.-Y.; Duh, C.-Y.; Fang, L.-S.; Soong, K.; Lee, T.-J. *J. Nat. Prod.* **1996**, *59*, 935–938.
- Sheu, J.-H.; Sung, P.-J.; Cheng, M.-C.; Liu, H.-Y.; Fang, L.-S.; Duh, C.-Y.; Chiang, M. Y. *J. Nat. Prod.* **1998**, *61*, 602–608.
- Sheu, J.-H.; Sung, P.-J.; Su, J.-H.; Duh, C.-Y.; Chiang, M. Y. *Tetrahedron* **1999**, *55*, 14555–14564.
- Sheu, J.-H.; Chen, S.-P.; Sung, P.-J.; Chiang, M. Y.; Dai, C.-F. *Tetrahedron Lett.* **2000**, *41*, 7885–7888.
- Sung, P.-J.; Su, J.-H.; Duh, C.-Y.; Chiang, M. Y.; Sheu, J.-H. *J. Nat. Prod.* **2001**, *64*, 318–323.
- Sheu, J.-H.; Ahmed, A. F.; Shiue, R.-T.; Dai, C.-F.; Kuo, Y.-H. *J. Nat. Prod.* **2002**, *65*, 1904–1908.
- Duh, C.-Y.; Hou, R.-S.; Wang, S.-K.; Chang, T.-T.; Wang, Y.; Lee, G.-H.; Soong, K.; Fang, L.-S. *The Chin. Pharm. J.* **1993**, *45*, 399–407.
- Alley, M. C.; Scudiero, D. A.; Monks, A.; Hursey, M. L.; Czerwinski, M. J.; Fine, D. L.; Abbott, B. J.; Mayo, J. G.; Shoemaker, R. H.; Boyd, M. R. *Cancer Res.* **1988**, *48*, 589–601.
- Scudiero, D. A.; Shoemaker, R. H.; Paull, K. D.; Monks, A.; Tierney, S.; Nofziger, T. H.; Currens, M. J.; Seniff, D.; Boyd, M. R. *Cancer Res.* **1988**, *48*, 4827–4833.